Evaluation of the Abbott ARCHITECT Chagas prototype assay

被引：19
|
作者：
Praast, Gerald [1 ]
Herzogenrath, Joerg [1 ]
Bernhardt, Stephanie [1 ]
Christ, Heike [1 ]
Sickinger, Eva [1 ]
机构：
[1] Abbott GmbH & Co KG, D-65205 Wiesbaden, Germany
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2011年 / 69卷 / 01期
关键词：
Chagas disease; Recombinant antigens; Chagas IgG; TRYPANOSOMA-CRUZI ANTIGENS; SEROLOGICAL DIAGNOSIS; RECOMBINANT ANTIGENS; SYNTHETIC PEPTIDE; DISEASE; ANTIBODIES; PROTEIN; TESTS;
D O I：
10.1016/j.diagmicrobio.2010.08.019
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Serologic tests are established tools for the diagnosis of Chagas disease applied to support a safe blood supply in endemic countries. However, sensitivity and specificity of most commercially available enzyme-linked immunosorbent assays (ELISAs) are not regarded as adequate enough to rely on a single assay to determine the Trypanosoma cruzi infection status of a blood donor or a patient. The overall assay performance is driven by the general choice of antigens and the actual antigen cocktail provided in the test. In this report we describe key performance data of the Abbott ARCHITECT Chagas prototype assay in comparison to the well-recognized bioMerieux ELISA cruzi assay. The ARCHITECT assay demonstrated superior specificity (99.99% versus 99.93%) and sensitivity (99.85% versus 98.38%), along with excellent precision, thus showing the potential to serve as single assay to determine the T. cruzi status of a given blood unit or diagnostic specimen on a fully automated instrument platform. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码：74 / 81
页数：8
相关论文
共 50 条
  • [21] Analytical multi-site evaluation of the Abbott ARCHITECT® tacrolimus assay
    Wallemacq, P.
    Goffinet, J.
    O'Morchoe, S.
    Rosiere, T.
    Dickson, D.
    Schmidt, E.
    Labalette, M.
    CLINICAL CHEMISTRY, 2007, 53 (06) : A91 - A91
  • [22] Phenobarbital assay evaluation on the Abbott Architect: Something old, something new
    Beriault, Daniel
    Martens, Paul
    Yip, Paul
    CLINICAL BIOCHEMISTRY, 2015, 48 (15) : 1025 - 1025
  • [23] Analytical multi-site evaluation of the Abbott ARCHITECT Cyclosporine assay
    Maine, G. T.
    Wallemacq, P.
    Ait-Youcef, H.
    Berg, K.
    Schmidt, E.
    Young, J.
    Schmid, R.
    Aimo, G.
    Marquet, P.
    Wonigeit, K.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A13 - A13
  • [24] Analytical multi-site evaluation of the Abbott ARCHITECT Tacrolimus assay
    Kahn, S. E.
    Vazquez, D.
    Meyer, P.
    Dickson, D.
    Schmidt, E.
    Castellani, W.
    Pederson, E.
    Edwards, M.
    Haverstick, D.
    Yabut, O.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A19 - A19
  • [25] Analytical multi-site evaluation of the Abbott architect® sirolimus assay
    Schmid, R. W.
    Lotz, J.
    Schweigert, R.
    Kergueris, M. F.
    Aimo, G.
    Friese, J.
    Rosiere, T.
    Maine, G.
    Dickson, D.
    Kenney, D.
    Lacklier, K.
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 507 - 507
  • [26] Analytical multi-site evaluation of the Abbott ARCHITECT® sirolimus assay
    Schmid, R.
    Lotz, J.
    Schweigert, R.
    Friese, J.
    Rosiere, T.
    Dickson, D.
    Kenney, D.
    Lackner, K.
    CLINICAL CHEMISTRY, 2007, 53 (06) : A93 - A93
  • [27] Multi-site Analytical Evaluation of the Abbott ARCHITECT Tacrolimus Assay
    Wallemacq, Pierre
    Goffinet, Jean-Sebastien
    O'Morchoe, Susan
    Rosiere, Thomas
    Maine, Gregory T.
    Labalette, Myriam
    Aimo, Giuseppe
    Dickson, Diana
    Schmidt, Ed
    Schwinzer, Reinhard
    Schmid, Rainer W.
    THERAPEUTIC DRUG MONITORING, 2009, 31 (02) : 198 - 204
  • [28] Analytical evaluation of the Abbott ARCHITECT cyclosporine assay in comparison to LC/MS/MS and Abbott TDX/FLX
    Maine, G. T.
    Edwards, M.
    Haverstick, D. M.
    Sluss, P.
    Young, J.
    Schmidt, E.
    Kettlety, T.
    CLINICAL BIOCHEMISTRY, 2008, 41 (14-15) : 1274 - 1274
  • [29] Performance Evaluation of a Prototype Architect Antibody Assay for Babesia microti
    Cheng, Kevin
    Coller, Kelly E.
    Marohnic, Christopher C.
    Pfeiffer, Zachary A.
    Fino, James R.
    Elsing, Randee R.
    Bergsma, Janet
    Marcinkus, Marilee A.
    Kar, Alak K.
    Gumbs, Orlando H.
    Otis, Kathy S.
    Fishpaugh, Jeffrey
    Schultz, Phillip W.
    Pope, Mark R.
    Narvaez, Alfredo R.
    Wong, Susan J.
    Madison-Antenucci, Susan
    Leary, Thomas P.
    Dawson, George J.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2018, 56 (08)
  • [30] Analytical performance of the Abbott ARCHITECT® ProGRP assay
    Meany, D. L.
    Dua, R.
    Elliott, D. J.
    Yamada, T.
    Kinukawa, H.
    Chan, S.
    Dowell, B.
    Chan, D. W.
    Sokoll, L. J.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A131 - A131
12345